Dipexium Pharmaceuticals Company Profile (NASDAQ:DPRX)

Analyst Ratings

Consensus Ratings for Dipexium Pharmaceuticals (NASDAQ:DPRX) (?)
Ratings Breakdown: 1 Strong Buy Rating(s)
Consensus Rating:Strong Buy (Score: 4.00)
Consensus Price Target: $22.00 (109.92% upside)

Analysts' Ratings History for Dipexium Pharmaceuticals (NASDAQ:DPRX)
Show:
DateFirmActionRatingPrice TargetActions
3/25/2016Raymond James Financial Inc.Lower Price TargetStrong-Buy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Dipexium Pharmaceuticals (NASDAQ:DPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/12/2016Q116($0.52)($0.56)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/16/2015Q315($0.47)($0.49)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.43)($0.47)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.44)($0.49)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/14/2015($0.44)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/24/2015Q414$0.52($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.49)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.37)($0.46)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dipexium Pharmaceuticals (NASDAQ:DPRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.51)($0.51)($0.51)
Q3 20161($0.41)($0.41)($0.41)
Q4 20161($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dipexium Pharmaceuticals (NASDAQ:DPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Dipexium Pharmaceuticals (NASDAQ:DPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/21/2014Jack H DeanDirectorBuy3,000$9.00$27,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2014David GarrettVPBuy2,083$12.00$24,996.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2014Thomas L HarrisonDirectorBuy2,000$12.00$24,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Dipexium Pharmaceuticals (NASDAQ:DPRX)
DateHeadline
07/28/16 02:22 PMDipexium Pharmaceuticals to Hold Second Quarter 2016 Financial Results Conference Call on Thursday, August …
07/28/16 06:18 AMDipexium Pharmaceuticals to Hold Second Quarter 2016 Financial Results Conference Call on Thursday, August 4, 2016, at 8:30 a.m. ET - [at noodls] - NEW YORK, July 28, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) will release its financial results for the quarter ended June 30, 2016, on Thursday, August 4, 2016 at 7:00 a.m. ET. ...
06/20/16 03:09 PMDipexium Pharmaceuticals' Locilex® Microbiology Data Presented at ASM Microbe 2016 Conference - [at noodls] - NEW YORK, June 20, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream ...
06/06/16 01:33 PMDipexium Pharmaceuticals, Inc. :DPRX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
05/26/16 08:28 AMDIPEXIUM PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/16/16 07:32 AMDipexium Announces Completion of Enrollment Objective in OneStep-1 Pivotal Phase 3 Clinical Trial - [at noodls] - NEW YORK, May 16, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), ...
05/13/16 05:57 AMADRO Earns Milestone Payment, Hope & Allstar Await CAPR, CATB Ahead Of Time - KOOL closed Thursday's trading at $2.21, down 3.91%. Dipexium Pharmaceuticals Inc. (DPRX) has completed patient enrollment objective in its phase III clinical trial of Locilex for the treatment of patients with mild infections of diabetic foot ulcers ...
05/12/16 06:07 AMQ1 2016 Dipexium Pharmaceuticals Inc Earnings Release - Before Market Open -
05/12/16 06:00 AMDipexium Pharmaceuticals Announces Completion of Enrollment Objective in OneStep-2 Pivotal Phase 3 Clinical Trial and First Quarter 2016 Financial Results - [PR Newswire] - NEW YORK, May 12, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), ...
05/09/16 07:18 AMDipexium Pharmaceuticals to Hold First Quarter 2016 Financial Results Conference Call on Thursday, May 12, 2016, at 8:30 a.m. ET - [at noodls] - NEW YORK, May 9, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) will release its financial results for the quarter ended March 31, 2016, on Thursday, May 12, 2016 at 7:00 a.m. ET. The ...
04/29/16 07:40 AMDipexium Pharmaceuticals (DPRX) Jumps: Stock Rises 7.5% -
04/27/16 03:24 PMIs Allergan On The Prowl For New Deals? -
04/27/16 07:03 AMWill Dipexium Pharmaceuticals (DPRX) Continue to Surge Higher? -
04/21/16 06:14 AMDipexium Pharmaceuticals Incorporated (NASDAQ:DPRX) Short Interest Increased By 10.68% - The stock decreased 1.84% or $0.18 on April 20, hitting $9.58. Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) has declined 27.92% since September 15, 2015 and is downtrending. It has underperformed by 34.20% the S&P500. Dipexium Pharmaceuticals, Inc. is a late ...
04/08/16 07:52 AMWhy You Shouldn't Bet Against Dipexium Pharmaceuticals (DPRX) Stock -
03/28/16 07:21 AMDipexium Pharmaceuticals Announces Issuance of Locilex® Patent in Japan - [at noodls] - NEW YORK, March 28, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream ...
03/28/16 07:04 AM8:04 am Dipexium Pharmaceuticals announces issuance of Locilex patent in Japan -
03/23/16 06:09 AMDipexium Pharmaceuticals Reports 2015 Financial Results - [at noodls] - NEW YORK, March 23, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream ...
03/23/16 06:07 AMQ4 2015 Dipexium Pharmaceuticals Inc Earnings Release - Before Market Open -
03/22/16 11:00 AMDIPEXIUM PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report -
03/18/16 10:28 AMImplied IWC Analyst Target Price: $86 - ... upside to their analyst target prices are HTG Molecular Diagnostics Inc (HTGM), pSivida Corp (PSDV), and Dipexium Pharmaceuticals Inc (DPRX). Although HTGM has traded at a recent price of $2.61/share, the average analyst target is 423.60% higher at $13 ...
03/14/16 06:00 AMDipexium Pharmaceuticals to Hold Year End 2015 Financial Results Conference Call on Wednesday, March 23, 2016, 8:30 a.m. ET -
03/02/16 07:00 AMDipexium Pharmaceuticals Announces Presentation at Raymond James 37th Annual Institutional Investors Conference - [PR Newswire] - NEW YORK, March 2, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream ...
02/17/16 03:30 PMDIPEXIUM PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements a -
02/04/16 07:00 AMDipexium Pharmaceuticals Reaches 75% Enrollment Milestone in Pivotal Phase 3 Clinical Trials - [PR Newswire] - NEW YORK, Feb. 4, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), ...
02/01/16 07:20 AMDipexium Pharmaceuticals Announces Issuance of Locilex® Patents in Australia and New Zealand - [at noodls] - NEW YORK, Feb. 1, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), ...
01/29/16 07:21 AMDipexium Pharmaceuticals Announces Presentation at 18th Annual BIO CEO & Investor Conference - [at noodls] - NEW YORK, Jan. 29, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream ...
01/27/16 09:15 AMDipexium Pharmaceuticals, Inc. (DPRX) - 16-Nov-15 DIPEXIUM PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement 13-Nov-15 DIPEXIUM PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report 13-Aug-15 DIPEXIUM PHARMACEUTICALS, INC. Files ...
01/11/16 01:30 PMDIPEXIUM PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
01/06/16 06:21 AMDipexium Pharmaceuticals Announces Presentation at Biotech Showcase™ 2016 - [at noodls] - NEW YORK, Jan. 6, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), ...
12/11/15 03:29 AMIs Dipexium Pharmaceuticals Inc (DPRX) A Good Stock To Buy? -
12/08/15 12:18 PMDIPEXIUM PHARMACEUTICALS, INC. Financials -
12/01/15 07:13 AMDipexium Pharmaceuticals Announces Presentation at Oppenheimer 26th Annual Healthcare Conference - [at noodls] - NEW YORK, Dec. 1, 2015 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), ...
11/16/15 08:02 AMDIPEXIUM PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement -
11/16/15 06:14 AMDipexium Pharmaceuticals Reports Third Quarter 2015 Financial Results - [at noodls] - NEW YORK, Nov. 16, 2015 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream ...
11/16/15 06:07 AMQ3 2015 Dipexium Pharmaceuticals Inc Earnings Release - 07:00 am ET -
11/13/15 03:23 PMDIPEXIUM PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report -
11/09/15 07:16 AMDipexium Pharmaceuticals to Hold Third Quarter 2015 Financial Results Conference Call on Monday, November 16, 2015, at 8:30 a.m. ET - [at noodls] - NEW YORK, Nov. 9, 2015 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) will release its financial results for the quarter ended September 30, 2015, on Monday, November 16, 2015 at 7:00 a.m. ...

Social

About Dipexium Pharmaceuticals

Dipexium Pharmaceuticals logoDipexium Pharmaceuticals, Inc. is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI). As a topical antibiotic, Locilex affects only the area to which it is applied, and does not spread to the entire body through the bloodstream, which is host to a number of different bacteria other than bacteria causing the skin infection. It is conducting over two Phase III clinical trials of Locilex for the treatment of Mild DFI (DPX-305 and DPX-306) in the United States. The Company has conducted over two separate Phase I skin irritation and skin sensitization studies. Locilex has demonstrated statistical non-inferiority to a systemic antibiotic in a randomized, active-controlled double blind, multi-center clinical study in patients with Mild or Moderate DFI.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: DPRX
  • CUSIP:
Key Metrics:
  • Previous Close: $10.48
  • 50 Day Moving Average: $10.40
  • 200 Day Moving Average: $9.53
  • P/E Ratio: N/A
  • P/E Growth: -0.12
  • Market Cap: $108.48M
  • Beta: 1.82
  • Current Year EPS Consensus Estimate: $-2.18 EPS
  • Next Year EPS Consensus Estimate: $-1.91 EPS
Additional Links:
Dipexium Pharmaceuticals (NASDAQ:DPRX) Chart for Friday, July, 29, 2016